Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Targovax ASA ( (GB:0RIS) ) has issued an announcement.
Circio Holding ASA has announced the conversion of NOK 2,500,000 worth of convertible bonds into 4,146,166 new shares, increasing its share capital to NOK 67,792,746. This move reflects the company’s ongoing efforts to strengthen its financial position and support its innovative biotechnology initiatives, including the development of its circVec platform and TG01 program.
More about Targovax ASA
Circio Holding ASA is a biotechnology company focused on developing advanced circular RNA vector expression technology for next-generation nucleic acid medicine. Their proprietary circVec platform is designed for enhanced gene and cell therapies, offering significant improvements in RNA stability and protein expression. The company also continues to advance its immuno-oncology program, TG01, targeting RAS-mutated cancers through collaborations.
YTD Price Performance: -12.68%
Average Trading Volume: 545,900
Current Market Cap: NOK67.48M
For detailed information about 0RIS stock, go to TipRanks’ Stock Analysis page.